{"id":378532,"date":"2025-11-04T09:58:00","date_gmt":"2025-11-04T01:58:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=378532"},"modified":"2025-11-04T09:58:00","modified_gmt":"2025-11-04T01:58:00","slug":"%e5%8f%a3%e9%a0%ad%e5%a0%b1%e5%91%8a%ef%bc%81%e7%b6%ad%e7%ab%8b%e5%bf%97%e5%8d%9a5%e9%a0%85%e8%a1%80%e6%b6%b2%e8%85%ab%e7%98%a4%e9%a0%98%e5%9f%9f%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e9%87%8d%e7%a3%85","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=378532","title":{"rendered":"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703"},"content":{"rendered":"<div>\n<p><span class=\"legendSpanClass\">\u5357\u4eac<\/span><span class=\"legendSpanClass\">2025\u5e7411\u67084\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31<span id=\"spanHghlt182c\">\u300c<\/span>\u7dad\u7acb\u5fd7\u535a<span id=\"spanHghltd5d4\">\u300d<\/span>\u6216<span id=\"spanHghlt182c\">\u300c<\/span>\u516c\u53f8<span id=\"spanHghltd5d4\">\u300d<\/span>\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002<\/p>\n<p class=\"prntac\"><b>LBL-034<\/b><b>\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a<span id=\"spanHghltf823\">\u6578\u64da<\/span>\u4eae\u76f8\u5927\u6703\u767c\u8a00<\/b><\/p>\n<p>\u6458\u8981\u6a19\u984c: A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma<br \/>\u6458\u8981\u865f\uff1a91<br \/>\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a<br \/>\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 <span class=\"xn-chron\">9:30 AM<\/span> \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09<br \/>\u5831\u544a\u5730\u9ede\uff1aOCCC &#8211; West Hall D2<br \/>\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531<b>\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b<\/b><b>17<\/b><b>\u5bb6\u4e2d\u5fc3\u958b\u5c55<\/b>\u3002LBL-034\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\/mg\u5291\u91cf\u7d44\u3002<b>\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728<\/b><b>ASH<\/b><b>\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002<\/b><\/p>\n<p>\u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\/\u2161 study in relapsed\/refractory multiple myeloma<br \/>\u6458\u8981\u865f\uff1a4070<br \/>\u985e\u578b\uff1a\u58c1\u5831<br \/>\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 <span class=\"xn-chron\">6:00 PM<\/span> \u2013 <span class=\"xn-chron\">8:00 PM<\/span><br \/>\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC &#8211; West Halls B3-B4<\/p>\n<p>\u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model<br \/>\u6458\u8981\u865f\uff1a2155<br \/>\u985e\u578b\uff1a\u58c1\u5831<br \/>\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 <span class=\"xn-chron\">5:30 PM<\/span> \u2013 <span class=\"xn-chron\">7:30 PM<\/span><br \/>\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC &#8211; West Halls B3-B4<\/p>\n<p>\u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\/refractory multiple myeloma<br \/>\u6458\u8981\u865f\uff1a6824<br \/>\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868<\/p>\n<p class=\"prntac\"><b>LBL-076<\/b><b>\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef<\/b><\/p>\n<p>\u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\/refractory multiple myeloma<br \/>\u6458\u8981\u865f\uff1a3302<br \/>\u985e\u578b\uff1a\u58c1\u5831<br \/>\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 <span class=\"xn-chron\">6:00 PM<\/span> \u2013 <span class=\"xn-chron\">8:00 PM<\/span><br \/>\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC &#8211; West Halls B3-B4<br \/>LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002<\/p>\n<p><b>\u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a<\/b>\uff1a<span id=\"spanHghlt182c\">\u300c<\/span>\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01<span id=\"spanHghltd5d4\">\u300d<\/span><\/p>\n<p><b>\u95dc\u65bc<\/b><b>LBL-034<\/b><\/p>\n<p>LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002<\/p>\n<p>LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002<\/p>\n<p><b>\u95dc\u65bc<\/b><b>LBL-076<\/b><\/p>\n<p>LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002<\/p>\n<p><b>\u95dc\u65bc\u7dad\u7acb\u5fd7\u535a<\/b><\/p>\n<p>\u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u5357\u4eac2025\u5e7411\u67084\u65e5 \/\u7f8e&#8230;<\/p>\n","protected":false},"author":16,"featured_media":199219,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-378532","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u5357\u4eac2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ -- \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31\u300c\u7dad\u7acb\u5fd7\u535a\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002 LBL-034\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\u5927\u6703\u767c\u8a00 \u6458\u8981\u6a19\u984c: A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a91\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 9:30 AM \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09\u5831\u544a\u5730\u9ede\uff1aOCCC - West Hall D2\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b17\u5bb6\u4e2d\u5fc3\u958b\u5c55\u3002LBL-034\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\/mg\u5291\u91cf\u7d44\u3002\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728ASH\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002 \u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\/\u2161 study in relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a4070\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model\u6458\u8981\u865f\uff1a2155\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 5:30 PM \u2013 7:30 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a6824\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868 LBL-076\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef \u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a3302\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a\uff1a\u300c\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01\u300d \u95dc\u65bcLBL-034 LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002 LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002 \u95dc\u65bcLBL-076 LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u95dc\u65bc\u7dad\u7acb\u5fd7\u535a \u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=378532\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u5357\u4eac2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ -- \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31\u300c\u7dad\u7acb\u5fd7\u535a\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002 LBL-034\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\u5927\u6703\u767c\u8a00 \u6458\u8981\u6a19\u984c: A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a91\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 9:30 AM \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09\u5831\u544a\u5730\u9ede\uff1aOCCC - West Hall D2\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b17\u5bb6\u4e2d\u5fc3\u958b\u5c55\u3002LBL-034\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\/mg\u5291\u91cf\u7d44\u3002\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728ASH\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002 \u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\/\u2161 study in relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a4070\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model\u6458\u8981\u865f\uff1a2155\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 5:30 PM \u2013 7:30 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a6824\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868 LBL-076\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef \u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a3302\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a\uff1a\u300c\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01\u300d \u95dc\u65bcLBL-034 LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002 LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002 \u95dc\u65bcLBL-076 LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u95dc\u65bc\u7dad\u7acb\u5fd7\u535a \u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=378532\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T01:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703\",\"datePublished\":\"2025-11-04T01:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532\"},\"wordCount\":252,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532\",\"name\":\"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"datePublished\":\"2025-11-04T01:58:00+00:00\",\"description\":\"\u5357\u4eac2025\u5e7411\u67084\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31\u300c\u7dad\u7acb\u5fd7\u535a\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002 LBL-034\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\u5927\u6703\u767c\u8a00 \u6458\u8981\u6a19\u984c: A first-in-human, phase I\\\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\\\/refractory multiple myeloma\u6458\u8981\u865f\uff1a91\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 9:30 AM \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09\u5831\u544a\u5730\u9ede\uff1aOCCC - West Hall D2\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b17\u5bb6\u4e2d\u5fc3\u958b\u5c55\u3002LBL-034\u5728\u5fa9\u767c\\\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\\\/mg\u5291\u91cf\u7d44\u3002\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728ASH\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002 \u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\\\/\u2161 study in relapsed\\\/refractory multiple myeloma\u6458\u8981\u865f\uff1a4070\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model\u6458\u8981\u865f\uff1a2155\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 5:30 PM \u2013 7:30 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\\\/refractory multiple myeloma\u6458\u8981\u865f\uff1a6824\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868 LBL-076\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef \u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\\\/refractory multiple myeloma\u6458\u8981\u865f\uff1a3302\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\\\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a\uff1a\u300c\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01\u300d \u95dc\u65bcLBL-034 LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002 LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\\\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\\\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002 \u95dc\u65bcLBL-076 LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u95dc\u65bc\u7dad\u7acb\u5fd7\u535a \u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":\"3000\",\"height\":\"1990\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378532#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5357\u4eac2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ -- \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31\u300c\u7dad\u7acb\u5fd7\u535a\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002 LBL-034\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\u5927\u6703\u767c\u8a00 \u6458\u8981\u6a19\u984c: A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a91\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 9:30 AM \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09\u5831\u544a\u5730\u9ede\uff1aOCCC - West Hall D2\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b17\u5bb6\u4e2d\u5fc3\u958b\u5c55\u3002LBL-034\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\/mg\u5291\u91cf\u7d44\u3002\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728ASH\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002 \u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\/\u2161 study in relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a4070\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model\u6458\u8981\u865f\uff1a2155\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 5:30 PM \u2013 7:30 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a6824\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868 LBL-076\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef \u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a3302\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a\uff1a\u300c\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01\u300d \u95dc\u65bcLBL-034 LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002 LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002 \u95dc\u65bcLBL-076 LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u95dc\u65bc\u7dad\u7acb\u5fd7\u535a \u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=378532","og_locale":"zh_TW","og_type":"article","og_title":"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u5357\u4eac2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ -- \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31\u300c\u7dad\u7acb\u5fd7\u535a\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002 LBL-034\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\u5927\u6703\u767c\u8a00 \u6458\u8981\u6a19\u984c: A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a91\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 9:30 AM \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09\u5831\u544a\u5730\u9ede\uff1aOCCC - West Hall D2\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b17\u5bb6\u4e2d\u5fc3\u958b\u5c55\u3002LBL-034\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\/mg\u5291\u91cf\u7d44\u3002\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728ASH\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002 \u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\/\u2161 study in relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a4070\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model\u6458\u8981\u865f\uff1a2155\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 5:30 PM \u2013 7:30 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a6824\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868 LBL-076\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef \u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a3302\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a\uff1a\u300c\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01\u300d \u95dc\u65bcLBL-034 LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002 LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002 \u95dc\u65bcLBL-076 LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u95dc\u65bc\u7dad\u7acb\u5fd7\u535a \u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com","og_url":"https:\/\/pingtungtimes.com.tw\/?p=378532","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2025-11-04T01:58:00+00:00","og_image":[{"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"","width":"","height":""}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_image":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378532"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703","datePublished":"2025-11-04T01:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378532"},"wordCount":252,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=378532","url":"https:\/\/pingtungtimes.com.tw\/?p=378532","name":"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","datePublished":"2025-11-04T01:58:00+00:00","description":"\u5357\u4eac2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ -- \u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08ASH\uff09\u5e74\u6703\u5c07\u65bc2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u570b\u4f5b\u7f85\u91cc\u9054\u5dde\u5967\u862d\u591a\u8209\u884c\uff0c\u5357\u4eac\u7dad\u7acb\u5fd7\u535a\u751f\u7269\u79d1\u6280\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u4ee5\u4e0b\u7c21\u7a31\u300c\u7dad\u7acb\u5fd7\u535a\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a9887.HK\uff09LBL-034\u3001LBL-076\u5169\u6b3e\u5728\u7814\u5275\u65b0\u85e5\u76845\u9805\u7814\u7a76\u6210\u679c\u88ab\u5927\u6703\u6536\u9304\uff0c\u5305\u62ec1\u7bc7\u53e3\u982d\u5831\u544a\u30013\u7bc7\u58c1\u5831\u5c55\u793a\u548c1\u7bc7\u7dda\u4e0a\u767c\u8868\u3002 LBL-034\uff1a\u591a\u9805\u7814\u7a76\u5165\u9078\uff0c\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\u5927\u6703\u767c\u8a00 \u6458\u8981\u6a19\u984c: A first-in-human, phase I\/II, open-label, multicenter, dose escalation and expansion study of LBL-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a91\u5831\u544a\u985e\u578b\uff1a\u53e3\u982d\u5831\u544a\u5831\u544a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 9:30 AM \u2013 9:45 AM\uff08\u5927\u6703\u9996\u65e5\u9996\u5834\u53e3\u982d\u5831\u544a\u5c08\u5834\u7b2c\u4e00\u500b\u5f59\u5831\uff09\u5831\u544a\u5730\u9ede\uff1aOCCC - West Hall D2\u672c\u7814\u7a76\uff08NCT06049290\uff09\u7531\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\u8def\u747e\u6559\u6388\u727d\u982d\uff0c\u5728\u5168\u570b17\u5bb6\u4e2d\u5fc3\u958b\u5c55\u3002LBL-034\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08RRMM\uff09\u60a3\u8005\uff0c\u5305\u62ec\u5177\u6709\u9ad8\u5371\u7279\u5fb5\u7684\u96e3\u6cbb\u4e9e\u7d44\uff0c\u8868\u73fe\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u4ee4\u4eba\u632f\u596e\u7684\u6297\u816b\u7624\u6d3b\u6027\uff0c\u5c24\u5176\u662f\u5728800-1200\u03bcg\/mg\u5291\u91cf\u7d44\u3002\u6700\u65b0\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u8cc7\u6599\u5c07\u5728ASH\u5927\u6703\u9996\u65e5\u7684\u9996\u500b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff0c\u6392\u5728\u7b2c\u4e00\u4f4d\u9032\u884c\u5f59\u5831\u3002 \u6458\u8981\u6a19\u984c: Pharmacokinetics, pharmacodynamics, and biomarkers of LBL-034, a GPRC5D-targeted T cell engager, in a first-in-human phase \u2160\/\u2161 study in relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a4070\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Proof of concept and mechanistic evaluation of LBL-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model\u6458\u8981\u865f\uff1a2155\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.06 5:30 PM \u2013 7:30 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4 \u6458\u8981\u6a19\u984c: Population pharmacokinetics (popPK) and exposure-response (ER) analyses of LBL-034, a potent GPRC5D T cell engager in patients with relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a6824\u985e\u578b\uff1a\u7dda\u4e0a\u767c\u8868 LBL-076\uff1a\u9996\u79c0\u5373\u9a5a\u8c54\uff0c\u81e8\u5e8a\u524d\u7814\u7a76\u7372\u570b\u969b\u8a8d\u53ef \u6458\u8981\u6a19\u984c: LBL-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed\/refractory multiple myeloma\u6458\u8981\u865f\uff1a3302\u985e\u578b\uff1a\u58c1\u5831\u5c55\u793a\u6642\u9593\uff1a\u7f8e\u570b\u6771\u90e8\u6642\u95932025.12.07 6:00 PM \u2013 8:00 PM\u5c55\u793a\u4f4d\u7f6e\uff1aOCCC - West Halls B3-B4LBL-076\u662f\u540c\u6642\u9776\u5411CD38\u3001GPRC5D\u53caCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u5177\u6709first-in-class\u6f5b\u529b\u3002\u5176\u7368\u7279\u7684\u5206\u5b50\u8a2d\u8a08\u65e8\u5728\u514b\u670d\u7531\u816b\u7624\u7570\u8cea\u6027\u5c0e\u81f4\u7684\u514d\u75ab\u9003\u9038\u548c\u6297\u539f\u4e1f\u5931\u554f\u984c\uff0c\u4e26\u5728\u5fa9\u767c\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u4e2d\u5be6\u73fe\u5f37\u6548\u4e14\u6301\u4e45\u7684\u7642\u6548\u3002\u81e8\u5e8a\u524d\u7814\u7a76\u8cc7\u6599\u986f\u793a\uff0cLBL-076\u5177\u6709\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u7dad\u7acb\u5fd7\u535a\u9996\u5e2d\u91ab\u5b78\u5b98\u8521\u52dd\u5229\u535a\u58eb\u8868\u793a\uff1a\u300c\u7dad\u7acb\u5fd7\u535a\u591a\u9805\u7814\u7a76\u6210\u679c\u96c6\u4e2d\u5165\u90782025 ASH\uff0c\u4ee5\u5353\u8d8a\u7684\u79d1\u7814\u5be6\u529b\u548c\u5275\u65b0\u6210\u679c\uff0c\u518d\u6b21\u5411\u5168\u7403\u5b78\u8853\u754c\u5c55\u793a\u4e86\u516c\u53f8\u5728\u816b\u7624\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u6df1\u539a\u7a4d\u6fb1\u8207\u9818\u5148\u5730\u4f4d\u3002\u5c24\u70ba\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u4e4b\u4e00\u2014\u2014LBL-034\uff0c\u6191\u85c9\u5176\u7368\u7279\u7684TCE\u5e73\u81fa\u5275\u65b0\u6a5f\u5236\u548c\u7a81\u7834\u6027\u7684\u81e8\u5e8a\u8cc7\u6599\uff0c\u7372\u9078\u4ee5\u5927\u6703\u53e3\u982d\u767c\u8a00\u5f62\u5f0f\u9032\u884c\u5c55\u793a\uff0c\u9019\u4e0d\u50c5\u662f\u5c0dLBL-034\u79d1\u5b78\u50f9\u503c\u7684\u5145\u5206\u80af\u5b9a\uff0c\u66f4\u662f\u570b\u969b\u5b78\u8853\u754c\u5c0d\u516c\u53f8\u5275\u65b0\u80fd\u529b\u7684\u9ad8\u5ea6\u8a8d\u53ef\uff01\u300d \u95dc\u65bcLBL-034 LBL-034\u662f\u9776\u5411GPRC5D\u53caCD3\u7684\u4eba\u6e90\u5316\u96d9\u7279\u7570\u6027T-cell engager\uff0c\u5229\u7528\u6211\u5011\u7684\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002LBL-034\u63a1\u75282:1\u7d50\u69cb\u8a2d\u8a08\uff0c\u64c1\u6709\u5169\u500b\u9776\u5411GPRC5D\u7684\u9ad8\u89aa\u548c\u529bFab\u53ca\u4e00\u500b\u9776\u5411CD3\u7684scFv\u3002LBL-034\u80fd\u5920\u6709\u6548\u5730\u91cd\u5b9a\u5411\u53ca\u555f\u52d5T\u7d30\u80de\u4ee5\u9776\u5411GPRC5D+\u764c\u7d30\u80de\uff0c\u540c\u6642\u4e0d\u6613\u8a98\u5c0eT\u7d30\u80de\u8870\u7aed\u53ca\u7d30\u80de\u6b7b\u4ea1\uff0c\u4e26\u5927\u5927\u964d\u4f4e\u7d30\u80de\u56e0\u6578\u91cb\u653e\u7d9c\u5408\u5f81\u53ca\u514d\u75ab\u6bd2\u6027\u7684\u98a8\u96aa\u3002 LBL-034\u5728\u81e8\u5e8a\u524d\u53ca\u81e8\u5e8a\u7814\u7a76\u4e2d\u5747\u8868\u73fe\u51fa\u826f\u597d\u7642\u6548\u4fe1\u865f\uff0c\u76ee\u524d\u6b63\u5728\u9032\u884cI\/II\u671f\u8a66\u9a57\u4ee5\u8a55\u4f30\u5176\u6cbb\u7642\u5fa9\u767c\u6027\/\u96e3\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u6f5b\u529b\u3002\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u7684\u8cc7\u6599\uff0c\u622a\u81f32024\u5e7411\u6708\uff0cLBL-034\u662f\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u50c5\u6b21\u65bc\u5f37\u751f\u3001\u4e2d\u570b\u81e8\u5e8a\u9032\u5ea6\u7b2c\u4e00\u7684\u9776\u5411GPRC5D\u7684CD3 T-cell engager\u30022024\u5e7410\u6708LBL-034\u7372\u5f97FDA\u7684\u5b64\u5152\u85e5\u8a8d\u5b9a(ODD)\uff0c\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u3002 \u95dc\u65bcLBL-076 LBL-076\u662f\u4e00\u6b3e\u6f5b\u5728\u9996\u5275\u9776\u5411CD38xGPRC5DxCD3\u7684\u4e09\u7279\u7570\u6027T\u7d30\u80de\u9023\u7d50\u5668\uff0c\u57fa\u65bc\u7dad\u7acb\u5fd7\u535a\u5c08\u6709LeadsBody\u5e73\u81fa\u958b\u767c\u3002\u8a72\u5206\u5b50\u53ef\u540c\u6642\u9776\u5411\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u7d30\u80de\u4e0a\u7d93\u904e\u9a57\u8b49\u7684\u9776\u9edeGPRC5D\u548cCD38\uff0c\u4e26\u689d\u4ef6\u6027\u555f\u52d5T\u7d30\u80de\u3002LBL-076\u5c0d\u8868\u9054\u4e0d\u540c\u6c34\u6e96GPRC5D\u548cCD38\u7684\u9aa8\u9ad3\u7624\u7d30\u80de\u8868\u73fe\u51fa\u5f37\u6548\u7684T\u7d30\u80de\u4f9d\u8cf4\u6027\u7d30\u80de\u6bd2\u4f5c\u7528\uff08TDCC\uff09\uff0c\u4e26\u4f34\u96a8T\u7d30\u80de\u555f\u52d5\u548c\u6eab\u548c\u7684\u7d30\u80de\u56e0\u6578\u91cb\u653e\u3002\u540c\u6642\uff0cLBL-076\u901a\u904e\u7d50\u69cb\u512a\u5316, \u964d\u4f4e\u4e86\u5c0d\u8868\u9054CD38\u7684\u514d\u75ab\u7d30\u80de\u6f5b\u5728\u7684\u7d30\u80de\u6bd2\u6027\u3002\u5728\u591a\u7a2e\u79fb\u690d\u6709\u4e0d\u540c\u6297\u539f\u8868\u9054\u6c34\u6e96MM\u816b\u7624\u7d30\u80de\u7684\u5c0f\u9f20\u6a21\u578b\u4e2d\uff0cLBL-076\u5747\u986f\u793a\u4e86\u986f\u8457\u7684\u6297\u816b\u7624\u6d3b\u6027\u3002 \u95dc\u65bc\u7dad\u7acb\u5fd7\u535a \u7dad\u7acb\u5fd7\u535a\u6210\u7acb\u65bc2012\u5e74\uff0c\u662f\u4e00\u5bb6\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u7684\u751f\u7269\u79d1\u6280\u516c\u53f8\uff0c\u81f4\u529b\u65bc\u5275\u65b0\u7642\u6cd5\u7684\u767c\u73fe\u3001\u958b\u767c\u53ca\u5546\u696d\u5316\uff0c\u4ee5\u6eff\u8db3\u4e2d\u570b\u53ca\u5168\u7403\u5728\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u91cd\u5927\u75be\u75c5\u65b9\u9762\u672a\u7372\u6eff\u8db3\u7684\u91ab\u7642\u9700\u6c42\u3002\u6211\u5011\u662f\u4e0b\u4e00\u4ee3\u816b\u7624\u514d\u75ab\u7642\u6cd5\u7684\u9818\u8dd1\u8005\uff0c\u64c1\u6709\u6db5\u84cb14\u6b3e\u5275\u65b0\u5019\u9078\u85e5\u7269\u7684\u5dee\u7570\u5316\u81e8\u5e8a\u7ba1\u7dda\uff0c\u5176\u4e2d6\u6b3e\u5df2\u6210\u529f\u9032\u5165\u81e8\u5e8a\u968e\u6bb5\uff0c4\u6b3e\u4e3b\u8981\u7522\u54c1\u5747\u8655\u65bc\u5168\u7403\u81e8\u5e8a\u9032\u5ea6\u9818\u5148\u7684\u5019\u9078\u85e5\u7269\u4e4b\u5217\u3002\u6211\u5011\u63a1\u7528\u79d1\u5b78\u9a45\u52d5\u7684\u7814\u767c\u65b9\u6cd5\uff0c\u5df2\u6210\u529f\u5efa\u7acb\u6db5\u84cb\u6297\u9ad4\u767c\u73fe\u53ca\u5de5\u7a0b\u3001\u9ad4\u5167\u53ca\u9ad4\u5916\u7642\u6548\u8a55\u4f30\u4ee5\u53ca\u6210\u85e5\u6027\u8a55\u4f30\u7684\u7d9c\u5408\u7814\u767c\u80fd\u529b\u3002\u6211\u5011\u4ea6\u958b\u767c\u4e86\u5305\u62ecLeadsBody\u5e73\u81fa\uff08CD3 T-Cell Engager\u5e73\u81fa\uff09\u3001X-body\u5e73\u81fa\uff084-1BB Engager\u5e73\u81fa\uff09\u3001TOPiKinectics\uff08ADC\u6280\u8853\u5e73\u81fa\uff09\u5728\u5167\u7684\u5c08\u6709\u6280\u8853\u5e73\u81fa\u3002\u6211\u5011\u7684\u6280\u8853\u5e73\u81fa\u662f\u6211\u5011\u6301\u7e8c\u5275\u65b0\u7684\u57fa\u77f3\uff0c\u4e26\u5df2\u901a\u904e\u96d9\u7279\u7570\u6027\u6297\u9ad4\u7d44\u5408\u7684\u81e8\u5e8a\u7d50\u679c\u5f97\u5230\u9a57\u8b49\u3002\u6211\u5011\u6210\u529f\u5efa\u7acb\u8d77\u4e86\u5728\u65e9\u671f\u7814\u767c\u3001\u8f49\u5316\u91ab\u5b78\u3001\u81e8\u5e8a\u958b\u767c\u3001CMC\u4ee5\u53ca\u696d\u52d9\u62d3\u5c55\u65b9\u9762\u7121\u7e2b\u929c\u63a5\u7684\u81ea\u4e3b\u80fd\u529b\u3002\u6211\u5011\u5019\u9078\u85e5\u7269\u7684\u5275\u65b0\u6027\u8cea\u53ca\u7af6\u722d\u512a\u52e2\uff0c\u914d\u5408\u6211\u5011\u5168\u7403\u8996\u91ce\u3001\u7a4d\u6975\u4e3b\u52d5\u7684\u7b56\u7565\u53ca\u9ad8\u6548\u7684\u81e8\u5e8a\u9a57\u8b49\u4f7f\u6211\u5011\u6210\u70ba\u982d\u90e8\u884c\u696d\u53c3\u8207\u8005\u53ca\u6295\u8cc7\u6a5f\u69cb\u5099\u53d7\u6b61\u8fce\u7684\u5408\u4f5c\u5925\u4f34\u3002\u66f4\u591a\u8cc7\u8a0a\u8acb\u8a2a\u554f\uff1awww.leadsbiolabs.com","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=378532"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":"3000","height":"1990"},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=378532#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u53e3\u982d\u5831\u544a\uff01\u7dad\u7acb\u5fd7\u535a5\u9805\u8840\u6db2\u816b\u7624\u9818\u57df\u7814\u7a76\u6210\u679c\u91cd\u78c5\u767b\u96782025 ASH\u5e74\u6703"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/378532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=378532"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/378532\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/199219"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=378532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=378532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=378532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}